HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of methylprednisolone on P50, 2,3 diphosphoglycerate and arteriovenous oxygen difference in acute myocardial infarction.

Abstract
In a double-blind randomized study, 30 mg/kg of methylprednisolone sodium succinate (MPN) or 15 mg/kg of mannitol placebo (PL) were infused in 28 patients after acute myocardial infarction. Measurements were obtained immediately before and after for 24 hours after the initial infusion. The partial pressure of oxygen at 50% saturation of hemoglobin (P50) did not change significantly in vitro or in vivo after MPN, whereas 2,3 diphosphoglycerate (2,3 DPG) increased from 13.2 to 14.2 mumol/g Hb (p < 0.05) in the group receiving PL. The arteriovenous oxygen difference (Ca-VO2) remained constant after MPN or PL. The cardiac index (CI) increased after MPN (p < 0.02) associated with an increase in the oxygen consumption index (CI X A-V O2) from 146 to 170 ml/min/m2 (p < 0.05). These data show that MPN increases CI after acute myocardial infarction, but has no specific effects on P50, 2,3 DPG or Ca-VO2.
AuthorsE S Kalter, R J Henning, L Thijs, J L Vincent, H Becker, R W Carlson, M H Weil
JournalCirculation (Circulation) Vol. 62 Issue 5 Pg. 970-4 (Nov 1980) ISSN: 0009-7322 [Print] United States
PMID6998597 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Diphosphoglyceric Acids
  • Hemoglobins
  • Placebos
  • Methylprednisolone Hemisuccinate
  • Oxygen
  • Methylprednisolone
Topics
  • Adult
  • Aged
  • Diphosphoglyceric Acids (blood)
  • Double-Blind Method
  • Female
  • Hemoglobins
  • Humans
  • Male
  • Methylprednisolone (analogs & derivatives)
  • Methylprednisolone Hemisuccinate (pharmacology)
  • Middle Aged
  • Myocardial Infarction (blood)
  • Oxygen (blood)
  • Placebos

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: